Pharmac is seeking clinical advice on whether weight loss medication should be funded in New Zealand.
One in three people over the age of 15 are classified as obese and one in eight children aged between two and 14.
Pharmac received two applications to fund Wegovy or semaglutide - a GLP-1 receptor agonist for weight loss.
Auckland University Professor of Molecular Medicine Peter Shepherd told Andrew Dickens despite it being a short-term fix, it's like any other medicine.
He says it's the same as heart disease or blood pressure medication - as soon as you go off them, they lose their effect as well.

Laura McClure: ACT Education Spokesperson on the Government backing down from changing homeschool laws
02:47

Nick Tuffley: ASB Chief Economist on the Reserve Bank's decision to hold the OCR at 2.25%
03:15

Simon Bridges: Auckland Business Chamber CEO on his expectations for Budget 2026
03:20